This perspective, was first shared in our Weekly View e-newsletter, which summarizes the week’s most significant drug pricing news. To subscribe, click here.
This week ICER announced that AHIP, the nation’s largest association of health plans, has agreed to a special subscription on behalf of its entire membership that will provide access to ICER Analytics, ICER’s cloud-based platform. ICER Analytics facilitates the use of ICER’s reports and underlying economic models to help all stakeholders understand the clinical effectiveness and value of drugs, allow tailored analyses of potential innovative benefit designs and payment methods, and inform drug price and coverage negotiation.
According to ICER’s President, Steve Pearson, MD, MSc, “We believe that AHIP’s special subscription on behalf of all its members represents a sentinel moment in the growth of the application of evidence on effectiveness and value in the US health care system. Over the past 16 years, ICER has dedicated itself to catalyzing more transparent public dialogue on value to support evidence-based pricing and access. The use of our work has grown as life sciences companies, payers, and state and federal policymakers all seek ways to achieve higher value in the health care system.”
AHIP joins a growing list of ICER Analytics subscribers, such as major pharmaceutical companies, insurers and pharmacy benefit managers, international health technology assessment (HTA) organizations, patient groups, academic institutions, Medicaid agencies, and federal and state agencies.
To learn more about AHIP’s subscription, click here.
To learn more about ICER Analytics or to request a free trial, click here.